Trending Stock News

Analysts at Leerink Swann Reiterate their Outperform rating for Allergan (AGN) with $242 Target Price per Share; Horizon Discovery Group plc (LON:HZD) Covered By 5 Bulls

Among 27 analysts covering Allergan Inc. (NYSE:AGN), 19 have Buy rating, 0 Sell and 8 Hold. Therefore 70% are positive. Allergan Inc. has $400 highest and $171.0 lowest target. $260.23’s average target is 52.73% above currents $170.39 stock price. Allergan Inc. had 108 analyst reports since July 29, 2015 according to SRatingsIntel. As per Tuesday, October 10, the company rating was maintained by Cowen & Co. The firm has “Buy” rating by Wells Fargo given on Wednesday, December 6. The stock has “Outperform” rating by RBC Capital Markets on Thursday, November 3. Morgan Stanley upgraded the stock to “Overweight” rating in Wednesday, November 29 report. The stock has “Buy” rating by UBS on Wednesday, January 10. The firm has “Buy” rating given on Wednesday, July 26 by Citigroup. On Tuesday, July 18 the stock rating was maintained by Cantor Fitzgerald with “Hold”. The rating was upgraded by Mizuho to “Buy” on Friday, August 19. As per Wednesday, May 10, the company rating was downgraded by Goldman Sachs. The rating was maintained by Goldman Sachs with “Buy” on Monday, April 18.

Among 6 analysts covering Horizon Discovery Group Plc (LON:HZD), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Horizon Discovery Group Plc had 80 analyst reports since July 28, 2015 according to SRatingsIntel. On Wednesday, October 28 the stock rating was maintained by Panmure Gordon with “Buy”. The firm has “Buy” rating by Numis Securities given on Monday, April 25. The firm has “Buy” rating given on Wednesday, November 25 by N+1 Singer. The rating was maintained by Beaufort Securities with “Speculative Buy” on Wednesday, April 27. The firm has “Buy” rating by Numis Securities given on Friday, September 8. Beaufort Securities maintained Horizon Discovery Group plc (LON:HZD) rating on Wednesday, May 31. Beaufort Securities has “Speculative Buy” rating and GBX 200 target. The stock of Horizon Discovery Group plc (LON:HZD) earned “Buy” rating by Numis Securities on Wednesday, June 1. The company was maintained on Wednesday, October 7 by N+1 Singer. Panmure Gordon maintained Horizon Discovery Group plc (LON:HZD) rating on Tuesday, September 22. Panmure Gordon has “Buy” rating and GBX 270 target. Panmure Gordon maintained the stock with “Buy” rating in Thursday, September 1 report. See Horizon Discovery Group plc (LON:HZD) latest ratings:

01/02/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
29/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
26/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
22/09/2017 Broker: N+1 Singer Rating: Buy Old Target: GBX 219.00 New Target: GBX 250.00 Reiteration
21/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
11/09/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
08/09/2017 Broker: Numis Securities Rating: Buy New Target: GBX 300.00 Maintain

Horizon Discovery Group plc, a life science company, engages in precision gene editing to design, build, and apply cells to advance human health worldwide. The company has market cap of 281.77 million GBP. The Company’s core capabilities are built around its proprietary transnational genomics platform, a suite of gene editing tools, such as rAAV, ZFN, and CRISPR to alter gene sequence in human or mammalian cell-lines. It currently has negative earnings. The firm offers approximately 23,000 cell lines, derived reagents, and in vivo models through direct sales, web-shop and ecommerce platform, and distribution partners.

The stock increased 10.85% or GBX 18.5 during the last trading session, reaching GBX 189. About 268,421 shares traded or 103.41% up from the average. Horizon Discovery Group plc (LON:HZD) has 0.00% since February 8, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment decreased to 0.33 in 2017 Q3. Its down 0.05, from 0.38 in 2017Q2. It is negative, as 3 investors sold Allergan plc shares while 3 reduced holdings. 0 funds opened positions while 2 raised stakes. 54,287 shares or 4.93% less from 57,100 shares in 2017Q2 were reported. Dowling & Yahnke Limited reported 0.04% in Allergan plc (NYSE:AGN). Cubic Asset Mgmt Ltd Liability Company stated it has 2,311 shares or 0.13% of all its holdings. Gemmer Asset Mgmt holds 116 shares or 0.01% of its portfolio. Connors Investor Services accumulated 1,000 shares. Mitchell Mcleod Pugh And Williams Incorporated reported 3,975 shares. Frontier Investment Management invested 0.51% of its portfolio in Allergan plc (NYSE:AGN). Eqis Cap Incorporated has 7,802 shares. American Research & Management, Massachusetts-based fund reported 33 shares. 6,825 were reported by Grassi Investment.

Analysts await Allergan plc (NYSE:AGN) to report earnings on February, 14. They expect $4.73 earnings per share, up 21.28% or $0.83 from last year’s $3.9 per share. AGN’s profit will be $1.57B for 9.01 P/E if the $4.73 EPS becomes a reality. After $4.15 actual earnings per share reported by Allergan plc for the previous quarter, Wall Street now forecasts 13.98% EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *